Literature DB >> 24702642

Use of corticosteroids for anorexia in palliative medicine: a systematic review.

Sarah Miller1, Louise McNutt, Mary-Ann McCann, Noleen McCorry.   

Abstract

BACKGROUND: Anorexia is a significant problem in patients approaching the end of life, for which corticosteroids are widely prescribed. It is not clear which regimen is the most safe and effective for this indication.
OBJECTIVE: The study objective was to identify the evidence for the use of corticosteroids, and the most safe and effective dosing regimen for management of anorexia in palliative care patients.
METHODS: A search of MEDLINE and CINAHL was carried out to identify original studies relevant to this question. These were reviewed against inclusion criteria and articles for inclusion were identified. Data was extracted and a narrative analysis was carried out. Subjects were adult patients with life-limiting diagnoses prescribed corticosteroids for anorexia in any care setting. Quality of studies was assessed using the system used by the Scottish Intercollegiate Guidelines Network for grading evidence.
RESULTS: Eight articles were identified that met the inclusion criteria. The corticosteroid drugs and dosing regimens used were wide ranging, and a variety of tools were used to assess appetite within these studies. All studies showed improvement in appetite with the corticosteroid used, although this did not always reach statistical significance. It was not possible to identify the most effective corticosteroid drug, dose, or duration of treatment from the identified studies: the best quality evidence was for an eight-week course of intravenous methylprednisolone; however the studies using this regimen had the highest attrition rates.
CONCLUSIONS: Corticosteroids are beneficial in treating anorexia in palliative care patients with malignancies; however there is no evidence for their use in anorexia due to end-stage nonmalignant disease. There is insufficient evidence to recommend any particular corticosteroid drug over another, or to recommend a dosing regimen.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24702642     DOI: 10.1089/jpm.2013.0324

Source DB:  PubMed          Journal:  J Palliat Med        ISSN: 1557-7740            Impact factor:   2.947


  13 in total

1.  A little help from steroids in oncology.

Authors:  Dominique Lossignol
Journal:  J Transl Int Med       Date:  2016-04-14

2.  Validating self-report and proxy reports of the Dexamethasone Symptom Questionnaire -Chronic for the evaluation of longer-term corticosteroid toxicity.

Authors:  Meera Agar; Eng-Siew Koh; Emma Gibbs; Elizabeth H Barnes; Elizabeth Hovey; Ann Livingstone; Kate Sawkins; Richard Chye; Melanie R Lovell; Katherine Clark; Janette Vardy; Madeleine King
Journal:  Support Care Cancer       Date:  2015-08-21       Impact factor: 3.603

Review 3.  Nutrition and Aging: a Practicing Oncologist's Perspective.

Authors:  Rishi Jain; Efrat Dotan
Journal:  Curr Oncol Rep       Date:  2017-09-07       Impact factor: 5.075

Review 4.  Medicinal cannabinoids in palliative care.

Authors:  Meera Agar
Journal:  Br J Clin Pharmacol       Date:  2018-08-12       Impact factor: 4.335

Review 5.  Do Patients Benefit from a Trial of Corticosteroids at the End of Life?

Authors:  Sriram Yennurajalingam; Eduardo Bruera
Journal:  Curr Treat Options Oncol       Date:  2022-04-01

Review 6.  Pharmacokinetics of Cannabis in Cancer Cachexia-Anorexia Syndrome.

Authors:  Stephanie E Reuter; Jennifer H Martin
Journal:  Clin Pharmacokinet       Date:  2016-07       Impact factor: 6.447

7.  The relationship between pro-inflammatory cytokines and pain, appetite and fatigue in patients with advanced cancer.

Authors:  Ørnulf Paulsen; Barry Laird; Nina Aass; Tor Lea; Peter Fayers; Stein Kaasa; Pål Klepstad
Journal:  PLoS One       Date:  2017-05-25       Impact factor: 3.240

Review 8.  The management strategies of cancer-associated anorexia: a critical appraisal of systematic reviews.

Authors:  Fangyuan Zhang; Aomei Shen; Yinghui Jin; Wanmin Qiang
Journal:  BMC Complement Altern Med       Date:  2018-08-09       Impact factor: 3.659

9.  Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy.

Authors:  David J Pinato; Ahmed Kaseb; Yinghong Wang; Anwaar Saeed; David Szafron; Tomi Jun; Sirish Dharmapuri; Abdul Rafeh Naqash; Mahvish Muzaffar; Musharraf Navaid; Uqba Khan; ChiehJu Lee; Anushi Bulumulle; Bo Yu; Sonal Paul; Petros Fessas; Neil Nimkar; Dominik Bettinger; Hannah Hildebrand; Tiziana Pressiani; Yehia I Abugabal; Nicola Personeni; Yi-Hsiang Huang; Jingky Lozano-Kuehne; Lorenza Rimassa; Celina Ang; Thomas U Marron
Journal:  J Immunother Cancer       Date:  2020-10       Impact factor: 13.751

10.  Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer.

Authors:  Diana V Maslov; Karine Tawagi; Madhav Kc; Victoria Simenson; Helen Yuan; Cameron Parent; Adi Bamnolker; Richa Goel; Zoe Blake; Marc R Matrana; Daniel H Johnson
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.